EBMT 2022 - 48th Annual Meeting of the European Group for Bone and Marrow Transplantation
Mar 19 - Mar 23, 2022 | PragueCzech Republic
LARVOL is not affiliated with 48th Annual Meeting of the European Group for Bone and Marrow Transplantation and all trademarks, logos, and brand names are property of their respective owners
Showing 98 abstracts linked to Trials
LISOCABTAGENE MARALEUCEL VERSUS STANDARD OF CARE (SALVAGE CHEMOTHERAPY FOLLOWED BY HIGH-DOSE CHEMOTHERAPY AND AUTOLOGOUS STEM CELL TRANSPLANTATION) AS SECOND-LINE THERAPY IN RELAPSED/REFRACTORY LBCL: TRANSFORM RESULTS
LONG-TERM FOLLOW-UP ANALYSIS OF ZUMA-5: A PHASE 2 STUDY OF AXICABTAGENE CILOLEUCEL (AXI-CEL) IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) INDOLENT NON-HODGKIN LYMPHOMA (INHL)
SUPERIORITY OF AXICABTAGENE CILOLEUCEL (AXI-CEL) IN SECOND-LINE (2L) LARGE B-CELL LYMPHOMA (LBCL) IN THE ELDERLY
TWO-YEAR FOLLOW-UP OF TRANSCEND NHL 001 (TRANSCEND), A MULTICENTER PHASE 1 STUDY OF LISOCABTAGENE MARALEUCEL(LISO-CEL) IN RELAPSED OR REFRACTORY (R/R) LARGE B-CELL LYMPHOMAS (LBCL)
DEVELOPMENT, SAFETY AND EFFICACY OF LOCALLY PRODUCED NOVEL BCMA CART CELLS FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA
PRIMARY ANALYSIS OF ZUMA‑7: A PHASE 3 RANDOMIZED TRIAL OF AXICABTAGENE CILOLEUCEL(AXI-CEL) VERSUS STANDARD‑OF‑CARE(SOC) THERAPY IN PATIENTS WITH RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA
HAPLO OR UNRELATED DONOR (UD) ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (ALLO HSCT) FOR PATIENTS OLDER THAN 55 YEARS: A RANDOMIZED MULTICENTER PHASE III STUDY.
MEASURABLE-RESIDUAL DISEASE GUIDED TREATMENT WITH AZACITIDINE IN MDS/AML PATIENTS AT IMMINENT RISK OF RELAPSE AFTER ALLOGENEIC STEM CELL TRANSPLANTATION: RESULTS OF THE PROSPECTIVE RELAZA2 TRIAL
PREDICTORS OF LONG TERM RESPONSE WITH CD28-BASED CD19 CAR T-CELLS IN CHILDREN AND YOUNG ADULTS WITH B-ALL
PROPHYLACTIC CORTICOSTEROID USE WITH AXICABTAGENE CILOLEUCEL (AXI-CEL) IN PATIENTS WITH RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA (R/R LBCL): 1-YEAR FOLLOW-UP OF ZUMA-1 COHORT 6 (C6)
TREATMENT OF ADULT ALL PATIENTS WITH THIRD-GENERATION CD19-DIRECTED CHIMERIC ANTIGEN RECEPTOR (CAR) T CELLS - RESULTS OF THE HEIDELBERG TRIAL 1 (HD-CAR-1 TRIAL)
TABELECLEUCEL FOR EPSTEIN–BARR VIRUS-DRIVEN POST-TRANSPLANT LYMPHOPROLIFERATIVE DISEASE FOLLOWING ALLOGENEIC HEMATOPOIETIC CELL (HCT) OR SOLID ORGAN TRANSPLANT (SOT) AFTER FAILURE OF RITUXIMAB +/- CHEMOTHERAPY (ALLELE)
POST-REMISSION TREATMENT PATTERN AND SURVIVAL OUTCOMES IN CONNECT® MYELOID DISEASE REGISTRY PATIENTS WITH ACUTE MYELOID LEUKEMIA
COMBINATION OF RUXOLITINIB AND INTERFERON Α-2B IS EFFECTIVE FOR TREATMENT OF RELAPSE OR MINIMAL RESIDUAL DISEASE AFTER ALLO-SCT: PHASE I/II STUDY OF NCT02185261 AND NCT02568241
PROSPECTIVE PHASE II STUDY OF PREEMPTIVE CHIMERISM-DRIVEN REDUCTION OF IMMUNOSUPPRESSION AFTER NON-MYELOABLATIVE CONDITIONING — SUBANALYSIS OF PATIENTS WITH MYELOID NEOPLASMS - EUDRACT #: 2007-002420-15